Sovaldi is currently priced at approximately $1,000 a pill, a total of $84,000 or more for a full course of treatment. But, Gilead Sciences intends to release a new interferon-free HCV treatment in October. The release of the new drug is expected to drive down costs.
During the briefing, Gilead Sciences Vice President Coy Stout and two cured HCV patients argued that the drug’s cost is less than that of a liver transplant.
More articles on gastroenterology:
Why do gastroenterologists need a GI-specific EMR system?
Is the MD/MBA combination the key to navigating healthcare today?
CRC test ColoMarker receives CE mark
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.